Shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) have received an average recommendation of “Buy” from the fourteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $83.80.
TRHC has been the subject of several recent analyst reports. BidaskClub cut shares of Tabula Rasa HealthCare from a “sell” rating to a “strong sell” rating in a report on Saturday, February 9th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $80.00 target price on shares of Tabula Rasa HealthCare in a report on Thursday, December 6th. Benchmark initiated coverage on shares of Tabula Rasa HealthCare in a report on Tuesday, January 8th. They issued a “buy” rating and a $85.00 target price for the company. Chardan Capital raised their target price on shares of Tabula Rasa HealthCare from $77.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Wednesday, December 26th.
Get Tabula Rasa HealthCare alerts:Shares of TRHC traded down $0.02 during midday trading on Friday, hitting $57.48. The stock had a trading volume of 14,674 shares, compared to its average volume of 402,745. Tabula Rasa HealthCare has a fifty-two week low of $32.34 and a fifty-two week high of $91.16. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 168.97, a PEG ratio of 3.68 and a beta of 1.79. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.49 and a quick ratio of 0.46.
In related news, CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 12th. The shares were sold at an average price of $75.87, for a total transaction of $606,960.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Samira Beckwith sold 1,733 shares of the firm’s stock in a transaction that occurred on Wednesday, December 12th. The stock was sold at an average price of $75.76, for a total transaction of $131,292.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,790 shares of company stock valued at $3,501,470. 14.00% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of TRHC. M&T Bank Corp bought a new position in Tabula Rasa HealthCare during the fourth quarter valued at approximately $33,749,000. BlackRock Inc. raised its position in Tabula Rasa HealthCare by 20.8% during the third quarter. BlackRock Inc. now owns 2,560,710 shares of the company’s stock valued at $207,904,000 after acquiring an additional 441,203 shares in the last quarter. Macquarie Group Ltd. raised its position in Tabula Rasa HealthCare by 1,418.9% during the fourth quarter. Macquarie Group Ltd. now owns 316,040 shares of the company’s stock valued at $20,151,000 after acquiring an additional 295,233 shares in the last quarter. Wells Fargo & Company MN raised its position in Tabula Rasa HealthCare by 673.0% during the third quarter. Wells Fargo & Company MN now owns 187,511 shares of the company’s stock valued at $15,224,000 after acquiring an additional 163,255 shares in the last quarter. Finally, Eagle Asset Management Inc. bought a new position in Tabula Rasa HealthCare during the third quarter valued at approximately $6,933,000. 79.99% of the stock is currently owned by hedge funds and other institutional investors.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Recommended Story: Economic Reports
No comments:
Post a Comment